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Edited by Felix WielandAbstract Hsp110s are divergent relatives of Hsp70 chaperones
that hydrolyze ATP. Hsp110s serve as Hsp70 nucleotide ex-
change factors and act directly to maintain polypeptide solubil-
ity. To date, the impact of peptide binding on Hsp110 ATPase
activity is unknown and an Hsp110/peptide aﬃnity has not been
measured. We now report on a peptide that binds to the yeast
Hsp110, Sse1p, with a KD of 2 nM. Surprisingly, the binding
of this peptide fails to stimulate Sse1p ATP hydrolysis. More-
over, an Hsp70-binding peptide is unable to associate with Sse1p,
suggesting that Hsp70s and Hsp110s possess partially distinct
peptide recognition motifs.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Hsp70s are a ubiquitous class of molecular chaperones that
are involved in protein folding, transport, degradation, and
assembly and disassembly of protein complexes, both in times
of cell stress and under normal growth conditions [1,2]. Hsp70s
contain a highly conserved, N-terminal nucleotide-binding do-
main (NBD), which allosterically regulates the peptide-binding
state in the C-terminal substrate-binding domain (SBD). In the
ATP-bound state, peptide aﬃnity is low, allowing substrate
binding and release, whereas in the ADP-bound state the pep-
tide aﬃnity is higher. This cycle can be modulated by DnaJ/
Hsp40 co-chaperones, which possess an Hsp70 interaction mo-
tif known as a J-domain. The stimulation of Hsp70 ATP
hydrolysis, which leads to peptide capture, can be achieved
by J-domain binding or by peptide binding. Subsequently, pep-
tide release can be triggered by nucleotide exchange factors
(NEFs) that help to liberate the bound ADP, facilitating
ATP rebinding.
The Hsp110s are divergent relatives of Hsp70s found only in
eukaryotes. Like Hsp70s, Hsp110s exhibit ATPase activity
[3,4]. Unlike Hsp70s, however, Hsp110s do not actively fold
proteins, but rather act as holdases to maintain the solubility
of denatured model protein substrates [3,5–7]. Hsp110s also
function as NEFs for Hsp70s [3,8,9]. Hsp110s most likely play
an important role in protein homeostasis because deletion of*Corresponding author. Fax: +1 412 624 4759.
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doi:10.1016/j.febslet.2008.05.047the predominant cytoplasmic Hsp110 in yeast, SSE1, leads
to a slow growth phenotype [10,11], and because Hsp110
over-expression in mammalian tissue culture cells confers ther-
motolerance [6]. Sse1p has also been proposed to mediate nas-
cent polypeptide folding at the ribosome in conjunction with
Hsp70s [12].
Sse1p shares 30% overall sequence identity with an abun-
dant, cytosolic yeast Hsp70, Ssa1p, and the two chaperones
associate [12,13]. The SBD in Sse1p is signiﬁcantly longer than
the analogous region in Ssa1p, and like other Hsp110-Hsp70
pairs, the sequence similarity between the proteins is largely
conﬁned to the NBDs. Nevertheless, the SBD of Sse1p, which
is conserved among Hsp110s, is predicted to bind peptides [14]
and the ability of the Sse1p SBD to exhibit holdase activity is
consistent with the presence of a peptide-binding site in
this domain. Thus, it was interesting that a putative peptide-
binding groove in the recent Sse1p crystal structure lacked
bound peptide [15]. This might have arisen because the adjoin-
ing NBD was ATP-bound and that Sse1p – like Hsp70s –
undergoes a nucleotide-dependent conformational change that
may catalyze peptide release [15,16]. Nevertheless, the orienta-
tion of SBD subdomains is quite diﬀerent between Sse1p and
Hsp70s, and it was not completely clear if the binding of pep-
tides to Sse1p would activate the ATPase activity. Moreover, it
was found that Sse1p nucleotide binding but not hydrolysis
was essential to support the viability of yeast containing site-
directed sse1 mutants in an sse1Dsse2D background, suggest-
ing that a tight coupling of ATP hydrolytic cycles to peptide
binding/release may not be vital for Hsp110 activity [17]. To
date, there have been no reports measuring the peptide aﬃnity
of Sse1p/Hsp110 or indicating directly whether peptide binding
activates ATP hydrolysis.
We now describe the identiﬁcation of a peptide that binds to
Sse1p with a KD of 2 nM, and discovered that ATP hydroly-
sis was unchanged upon peptide addition. In contrast, a pep-
tide substrate for Ssa1p activated the Hsp70s ATPase
activity but was unable to bind Sse1p. These data suggest that
Hsp110s and Hsp70 possess distinct peptide preferences, hint
that Hsp110s might exhibit uncoupled peptide binding and
ATP hydrolysis, and provide further support that the mecha-
nisms of action of Hsp70s and Hsp110s are unique.2. Materials and methods
2.1. Protein puriﬁcations
Hexahistidine-tagged forms of Sse1p and Ssa1p were isolated from
yeast cell extracts to a purity level >95% as described [5,18], and as
noted in the text, the presence of this amino acid extension on Sse1pblished by Elsevier B.V. All rights reserved.
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Fig. 1. The ATPase activity of yeast Hsp70 (Ssa1p) but not Hsp110
(Sse1p) is stimulated by select Hsp40 co-chaperones. The relative
steady-state ATPase activities of Ssa1p and Sse1p were examined in the
presence or absence of the indicated Hsp40s, as described in Section 2.
The ATPase activity in each experiment was then standardized to the
amount of ATP hydrolysis in the absence of added Hsp40. Data
represent the means of 3–8 independent determinations, ±S.E.;
P < 0.0001 for the Hlj1p-, Csp-, and Sis1p-mediated stimulation of
Ssa1p; the Sis1p-mediated stimulation of Sse1p was not signiﬁcant
(P < 0.16).
2394 J.L. Goeckeler et al. / FEBS Letters 582 (2008) 2393–2396did not inhibit its ATPase or holdase activities. Likewise, tagged Ssa1p
function in vitro or in vivo was unimpaired [18]. The absence of con-
taminating ATPases in the Sse1p preparation was conﬁrmed by mass
spectrometry of the puriﬁed protein sample. A soluble form of the
ER-associated Hlj1p chaperone was puriﬁed as described [19]. Puriﬁed
Sis1p was a generous gift from Dr. P. Needham (NIH) and the cysteine
string protein (Csp) was kindly provided by Dr. H. Zhang (University
of Pittsburgh School of Medicine).
To remove the hexahistine tag from Sse1p, the protein was treated
with recombinant bovine enterokinase followed by removal of the
enterokinase with anti-enterokinase-agarose as per the manufacturers
instructions (Sigma–Aldrich). The release of the hexahistidine tag from
Sse1p did not alter the ATPase activity of the Hsp110 or the inability
of Sse1p to be stimulated by J-domain containing proteins or peptide
(data not shown).
2.2. Peptides
Peptide ala-p5 (ALLLMYRR) is derived from the precursor of
chicken mitochondrial aspartate amino-transferase [20] and was syn-
thesized by the GenScript Corporation, Scotch Plains, NJ. A ﬂuores-
cein isothiocyanate (FITC) derivative was prepared as described [21].
The ‘‘LIC’’ peptide (LICGFRVVLMYRF; amino acids 256–268 in
ﬁreﬂy luciferase) was synthesized by the University of Pittsburgh Pep-
tide Synthesis Facility and labeled with 6-carboxylﬂuorescein (6CF)
using an epsilon-aminohexanoic linker at the N terminus. The purity
of each peptide was >89%, and the molecular masses were conﬁrmed
by mass spectrometry. The peptides were dissolved in DMSO
(FITC-ala-p5) or DMF (6CF-LIC) and stored at a ﬁnal concentration
of 6 mM at 20 C.
2.3. Assays for chaperone-mediated ATP hydrolysis and peptide binding
The ATPase activities of Ssa1p and Sse1p were assayed under stea-
dy-state conditions for 30 min at 30 C as described [22]. Where indi-
cated, a J-domain containing co-chaperone or an equivalent volume
of buﬀer was added at the start of the reaction such that the ﬁnal con-
centrations and ratio of the proteins were 2 lM co-chaperone: 1 lM
Hsp70/Hsp110. In other cases, the FITC-ala-p5 or 6CF-LIC peptide
(or an equal volume of solvent) was pre-incubated with the chaperones
at a ﬁnal concentration of 30 lM at 4 C for 15 min.
The binding of FITC-ala-p5 and 6CF-LIC to Ssa1p and Sse1p was
analyzed by incubating increasing concentrations of chaperone with
5 nM peptide in black 96-well microtiter plates (Corning), and ﬂuores-
cence polarization was measured in an Analyst AD instrument (Molec-
ular Devices). Polarization values are expressed in millipolarization
units (mPs) and were calculated using the equation mP = 1000 *
[(IS  ISB)  (IP  IPB)]/[(IS  ISB) + (IP  IPB)], where IS is the parallel
emission intensity measurement and IP is the perpendicular emission
intensity sample measured, and ISB and IPB are the corresponding mea-
surements for background (buﬀer).3. Results and discussion
To assess whether the regulation of ATP hydrolysis by Sse1p
is similar to that of Ssa1p, we ﬁrst puriﬁed hexahistidine-
tagged forms of both proteins and compared their ATPase
activities in the presence and absence of select Hsp40 co-
chaperones. As shown in Fig. 1, we found that the activity
of the Ssa1p but not Sse1p was signiﬁcantly enhanced by
two cytosolic yeast Hsp40s, Hlj1p and Sis1p, which are, respec-
tively, ER- and ribosome-associated Hsp70 co-chaperones that
are known to interact with Ssa1p [19,23]. A mammalian
Hsp40, Csp, which activates ATP hydrolysis by mammalian
Hsc70 [24] also selectively stimulated ATP hydrolysis by
Ssa1p. Notably, the unstimulated rates of ATP hydrolysis by
Ssa1p and Sse1p were very similar; the turnover numbers were
0.33 per minute for Ssa1p and 0.34 per minute for Sse1p. This
is consistent with the range of published values for the unstim-
ulated rates of ATP hydrolysis by Hsp70 chaperones [25–27].
Next, we employed a method that was previously used to iso-
late peptides that bound to the Escherichia coli Hsp70, DnaK[28] and Hsp40, DnaJ [29]. In brief, nitrocellulose blots contain-
ing partially overlapping 14 amino acid peptides derived from
ﬁreﬂy luciferase, an Sse1p substrate [5,30], were probed with
puriﬁed Sse1p. Peptides corresponding to select ‘‘hits’’ from this
analysis were synthesized and one peptide, designated ‘‘LIC’’,
was conjugated to 6-carboxyﬂuorescein (6CF) so that binding
could be assessed in solution. We found that 6CF-LIC associ-
ated with Sse1p with a KD of 2.3 nM (Fig. 2A, open circles).
This is higher than the aﬃnity of Hsp70 for other peptides,
such as p5 and APPY, measured in the presence of ADP or
in the absence of nucleotide (60 nM; [31,32]), but the binding
of 6CF-LIC to Ssa1p under these conditions (KD = 27 nM;
Fig. 2A, closed circles) was quite similar to the published
values for peptide binding. Furthermore, addition of unlabeled
LIC peptide to a ﬁnal concentration of 1 lM displaced 25%
of the bound 6CF-LIC under steady-state conditions; in con-
trast, incubation of Sse1p with 6CF-LIC in the presence of
ATP or ADP had no statistically signiﬁcant eﬀect on peptide
binding (data not shown), consistent with the conjecture that
a tight coupling between Sse1ps ATPase cycle and peptide
binding may not be vital (see Introduction). Based on these
data, we conclude that Sse1p has a signiﬁcantly higher binding
aﬃnity for the LIC peptide than Ssa1p.
To determine whether Sse1p could also bind to anHsp70 pep-
tide substrate, we made use of a FITC-conjugate of ala-p5 (see
Section 2). Although Ssa1p bound FITC-ala-p5 with a KD of
100–300 nM,no interactionwasobservedbetween this peptide
and Sse1p (Fig. 2B, compare closed to open circles). Of note, we
recently reported that the binding of FITC-ala-p5 to Hsp70 is
ATP-dependent [21], indicating the validity of using this modi-
ﬁed substrate to measure the peptide-binding aﬃnity for the
chaperone. Combined with the data presented in Fig. 2A, these
results indicate that Sse1p exhibits peptide-binding speciﬁcity
and that the peptide preferences for Sse1p and Ssa1p are not en-
tirely overlapping. A complete analysis of the peptide prefer-
ences of Sse1p will require continued analysis using peptide-
display technologies, but based onour datawe suggest that these
eﬀorts should prove informative.
Having identiﬁed 6CF-LIC as a high-aﬃnity peptide
substrate for Sse1p, we then examined whether the peptide
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Fig. 2. Sse1p exhibits high-aﬃnity peptide binding. The binding of (A) 6CF-LIC and (B) FITC-ala-p5 to Ssa1p and Sse1p were assayed as described
in Section 2. Ssa1p data are represented by closed circles () and Sse1p data are indicated by open circles (). Curve ﬁts are indicated by solid black
lines.
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Fig. 3. The ATPase activity of Sse1p is not enhanced by the addition
of a peptide substrate. Steady-state ATPase assays were performed as
described in the Materials and methods in the presence or absence of a
30-fold molar excess of FITC-ala-p5 or 6CF-LIC. Data represent the
means of 3–6 independent experiments, ±S.E. Note that only the
stimulation of Ssa1p by ala-p5 is signiﬁcant (P < 0.0004).
J.L. Goeckeler et al. / FEBS Letters 582 (2008) 2393–2396 2395stimulates the chaperones ATPase activity. Experiments using
FITC-ala-p5 were performed in parallel and the combined
data are summarized in Fig. 3. As anticipated, we found that
a 30-fold molar excess of ala-p5 signiﬁcantly enhanced the
ATPase activity of Ssa1p. In contrast, neither FITC-ala-p5
nor the binding peptide 6CF-LIC aﬀected the ATP hydrolytic
rate of Sse1p (Fig. 3).
Based on the sensitivity of the ﬂuorescence methods
employed in this study, our data also establish a means to
screen for small molecule compounds that might interfere with
peptide binding to Hsp110s. Because defects in Sse1p function
enhance the degradation of an atherosclerotic-inducing apoli-
poprotein (apoB) [33], we suggest that inhibitors that block
Hsp110-substrate binding in hepatic cells might provide a
means to lower circulating cholesterol levels. Furthermore,
mammalian Hsp110 and an ER-localized Hsp110 homolog,
Grp170, bind tumor-derived peptides and protein substrates,
and these chaperones have been used to trigger innate and
antigen-associated immunity [34]. Based on our data, one rea-
son Hsp110/Grp170 may be highly eﬀective in anti-cancer vac-
cines is that they have such a high-aﬃnity for peptide
substrates. Further studies can now be directed to test this
hypothesis.
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